Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar;24(3):e108-e120.
doi: 10.1016/S1470-2045(23)00012-8. Epub 2023 Feb 14.

Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group

Matthew J Ehrhardt  1 , Jan M Leerink  2 , Renée L Mulder  3 , Annelies Mavinkurve-Groothuis  3 , Wouter Kok  4 , Anju Nohria  5 , Paul C Nathan  6 , Remy Merkx  7 , Esmée de Baat  3 , Ogechukwu A Asogwa  3 , Roderick Skinner  8 , Hamish Wallace  9 , E A M Lieke Feijen  3 , Maëlle de Ville de Goyet  10 , Maya Prasad  11 , Edit Bárdi  12 , Vesna Pavasovic  13 , Helena van der Pal  3 , Brice Fresneau  14 , Charlotte Demoor-Goldschmidt  15 , Ulrike Hennewig  16 , Julia Steinberger  17 , Chris Plummer  18 , Ming Hui Chen  19 , Arco J Teske  20 , Nadia Haddy  21 , Elvira C van Dalen  3 , Louis S Constine  22 , Eric J Chow  23 , Gill Levitt  24 , Melissa M Hudson  25 , Leontien C M Kremer  26 , Saro H Armenian  27
Affiliations
Review

Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group

Matthew J Ehrhardt et al. Lancet Oncol. 2023 Mar.

Abstract

Survivors of childhood, adolescent, and young adult cancer, previously treated with anthracycline chemotherapy (including mitoxantrone) or radiotherapy in which the heart was exposed, are at increased risk of cardiomyopathy. Symptomatic cardiomyopathy is typically preceded by a series of gradually progressive, asymptomatic changes in structure and function of the heart that can be ameliorated with treatment, prompting specialist organisations to endorse guidelines on cardiac surveillance in at-risk survivors of cancer. In 2015, the International Late Effects of Childhood Cancer Guideline Harmonization Group compiled these guidelines into a uniform set of recommendations applicable to a broad spectrum of clinical environments with varying resource availabilities. Since then, additional studies have provided insight into dose thresholds associated with a risk of asymptomatic and symptomatic cardiomyopathy, have characterised risk over time, and have established the cost-effectiveness of different surveillance strategies. This systematic Review and guideline provides updated recommendations based on the evidence published up to September, 2020.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests AN reports research support from Amgen; a research contract with Bristol Myers Squibb; consulting fees from AstraZeneca, Boehringer Ingelheim, and Bantam Pharmaceuticals; and participation on a data safety monitoring board for Takeda Oncology. CP reports personal honoraria and expenses for presentation at education meetings from Amgen, Incyte, Ipsen, Novartis, and Servier. LSC reports grant funding from the University of Alabama for the Children's Oncology Group Guidelines, payment or honoraria for lectures or presentations from the American Society of Hematology and the University of Miami, and participation in the National Cancer Institute PDQ Pediatric Oncology Board. EJC is the Principal Investigator on a research grant to his institution from Abbott Laboratories. All other authors declare no competing interests.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

LinkOut - more resources